Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound
Jorge E Toblli, Gabriel Cao, Luis Rico, Margarita Angerosa Laboratory of Experimental Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina Background: Ferric carboxymaltose (FCM) is a stable, non-dextran-based intravenous iron complex used to...
Saved in:
Main Authors: | Toblli JE (Author), Cao G (Author), Rico L (Author), Angerosa M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose
by: Toblli JE, et al.
Published: (2014) -
Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease
by: Patricia Garcia-Ortega, et al.
Published: (2022) -
Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up
by: Antonio Lacquaniti, et al.
Published: (2020) -
Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
by: Lea Bombač Tavčar, et al.
Published: (2023) -
A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy
by: Sanjay Gupte, et al.
Published: (2024)